C4 Therapeutics, Inc. (NASDAQ:CCCC) Financings

C4 Therapeutics, Inc.

Financings

RaiseDate
Public offering of common stock and pre-funded warrants, each with a Class A Warrant and a Class B Warrant
Announced: US$125M–US$349.7M · US$2.47 a share · Warrants at US$2.22 · Jefferies +2
Dealers: Jefferies (co-lead), TD Cowen (co-lead), Evercore ISI (co-lead)
Buyers: RA Capital Management (led the offering); OrbiMed; Soleus Capital; Lynx1 Capital Management; Bain Capital Life Sciences
Use of proceeds: Fund ongoing and planned clinical trials of cemsidomide, other R&D, working capital and general corporate purposes
Oct 16, 2025

Read by 6ix AI from the company's releases